technology

press releases

Date Title and Summary Additional Formats
Toggle Summary BOTHELL, Wash., July 18, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 13, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 12, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 11, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary -- Pivotal PROMISE 1 top-line results show eptinezumab met primary and key secondary endpoints -- -- Beginning day 1 after first dose significant reduction in proportion of patients experiencing migraine -- -- Average of 1 in 5 patients had no migraines in any given month over months 1 through 6 -- View HTML
Toggle Summary BOTHELL, Wash., June 07, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), today announced four data presentations at the 59 th Annual Scientific Meeting of the American Headache Society in Boston from June 8-11, 2017. The presentations will highlight Phase 2b clinical data and View HTML
Toggle Summary BOTHELL, Wash., May 10, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Bank of America Merrill Lynch 2017 Health Care View HTML
Toggle Summary - Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24 to 48 hours after a single infusion - BOTHELL, Wash., April 28, 2017 (GLOBE NEWSWIRE) --  Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company View HTML
Toggle Summary Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017 Conference call set for 5 p.m. EDT today BOTHELL, Wash., April 27, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company View HTML
Toggle Summary - Eptinezumab rational design results in differentiated clinical profile for migraine prevention therapy - - Eptinezumab responders showed significant and sustained reduction in migraine days following a single infusion -   BOTHELL, Wash., April 24, 2017 (GLOBE NEWSWIRE) -- Alder View HTML